Medical Marijuana, Inc. Major Investment AXIM Biotech Files Patent On Controlled Release Chewing Gum To Provide Opioid Addiction Treatment

NEW YORK, June 26, 2017 — Medical Marijuana, Inc. (OTC:MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC QB:AXIM), a world leader in cannabinoid research and development, filed with the United States Patent and Trademark Office (USPTO) for U.S. Application Serial Number 62/410,469, a patent of invention that involves a chewing gum composition with controlled release of cannabinoids and opioid agonists and/or antagonists for addiction and/or dependence treatment. The chewing gum may also be used for treatment of chronic pain.

“We are proud of AXIM Biotech on this milestone achievement that brings the Company one step closer toward entering the $100 billion market in pain management,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “The future of pain medicine may be a high dose of cannabis and a low dose of opioids. Already, we are seeing the incidence of prescription drug overdose death 25% lower in states where medical cannabis is legal, presumably because patients are able to combine natural botanical cannabis and use lower dose opioids to control pain.”

In addition, by providing replacement opioids such as opioid agonists and/or antagonists and cannabinoids in a chewing gum form, users may avoid adverse effects caused by injection, smoking and other delivery methods. The act of chewing is also known to be neuroprotective, destressing, it induces the release of reward hormones such as dopamine and serotonin, and improves oral health.


An agonist is a chemical that binds to a receptor and activates the receptor to produce a biological response. Full opioid agonists activate the opioid receptors in the brain resulting in the full opioid effect. Examples of full opioid agonists include hydrocodone, methadone, morphine, opium, and oxycodone. Other opioids of lower potency and with less addictive potential such as methadone, buprenorphine bind to the same receptors in the central nerve system and thus may reduce craving sensation while minimizing adverse effects on users.

However, all opioid agonists to one degree or another have side effects such as decreased respiratory drive which may lead to asphyxia, nausea and vomiting, pneumonia, constipation, etc.


An antagonist is a chemical that blocks or dampens agonist-mediated responses. Opioid antagonists block opioids by attaching to the same opioid receptors without activating them. Examples of opioid antagonists are naltrexone and naloxone. The antagonists bind to the same receptors as agonists thus removing the opioids from these sites. Thus, the negative side effects of the agonists are diminished.


Cannabinoids and in particular cannabidiol (CBD) may decrease craving for narcotics. Cannabinoids may be provided in microencapsulated form, which may improve the chewing gum’s taste, prevent binding with the gum base, control cannabinoid release during mastication, and further improve bioavailability of the cannabinoids once entering the gastrointestinal tract.

About Medical Marijuana, Inc.

Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit

To see Medical Marijuana, Inc.’s video statement, click here.

Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.

About AXIM®

AXIM® Biotechnologies, Inc. (OTC: AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, please visit


This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.

Public Relations Contact:

Andrew Hard

Chief Executive Officer

CMW Media

P. 888-829-0070

[email protected]

Investor Relations Contact:

Shiwei Yin, Grayling

[email protected]

P. +1646 284-9474

Lucia Domville, Grayling

[email protected]

P. +1646 284-9416

Corporate Contact Info:

North American Address:

18 East 50th Street, 5 Floor

New York, NY 10022

+1 844 294 6246

European Address:

Boelewerf 32, Unit 3

2987 VD Ridderkerk, The Netherlands

+31 10 8209 227